Alizyme: Can Low Risk Last Forever?

Alizyme's GBP16.1 million, barely discounted placing and open offer illustrates its investors' faith in its low-risk business model and maturing pipeline. It also provides leverage for negotiating the out-licensing deals those investors now expect.

"One of the most unusual things about Cambridge-based Alizyme PLC is the business model on which it was founded," suggests Richard Palmer, PhD, who has fronted the company since joining it as COO in September 1996 from Glaxo Wellcome (now part of GlaxoSmithKline PLC ) and became CEO in March 1997. In 1995, when Alizyme started up, "the company didn't have any of its own intellectual property, they had no platform or anything from which to generate multiple products, and none of Alizyme's founders had ever worked in the industry," he says.

VCs wouldn't touch the company seven years ago. Alizyme instead had to go directly to the UK's Alternative Investment Market...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

Bristol Myers Squibb ASPIREs For Access In LMICs

BMS has launched a new cancer drug access program for low-to-middle income countries, focusing on addressing health inequities and widening accessibility.

This is a test

 

Just running through to check Confluence instructions make sense

H2 Investment Life Sciences Uptick Anticipated But Markets Remain Enduringly Cautious

 
• By 

Taylor Wessing investment partners share their thoughts about market trends, the surge in AI interest and the new UK government’s approach to the life sciences agenda.

WIAT Global: Addressing Inequalities And Following The CAR-T Journey After Treatment

 
• By 

The recent Women in Advanced Therapies Global event, delivered via an interactive 24-hour platform, hosted a number of biopharma speakers who drew on personal and industry-wide experiences, all aligned by a desire to break biases.

More from In Vivo

Vigya test infogram

add a desc test

Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.

Clone Test Oncology’s Next Decade: The Therapies And Players Reshaping A $400bn Future - Clone

 

Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.